摘要
目的探讨急性非静脉曲张性上消化道出血(ANVUGIB)患者痛风发作的影响因素。方法选取2018年6月至2022年6月随州市中心医院收治的既往确诊有痛风病史的105例ANVUGIB患者作为研究对象,按照治疗期间有无痛风发作分为痛风发作组(29例)与痛风未发作组(76例),通过单因素及多因素logistic回归分析痛风发作的影响因素。结果单因素分析结果显示,痛风发作组与痛风未发作组的体重指数(BMI)、血生化指标中总胆固醇(TC)和甘油三酯(TG)水平比较,差异有统计学意义(P<0.05)。多因素logistic回归分析结果显示,有无输血(β=0.218,OR=1.127,95%CI:1.013~1.296)、是否联用碳酸氢钠(β=0.374,OR=1.232,95%CI:0.913~1.384)、奥美拉唑(β=0.283,OR=1.093,95%CI:0.728~1.138)、艾司奥美拉唑(β=-0.103,OR=0.957,95%CI:0.649~1.264)、尿酸水平(β=0.329,OR=1.192,95%CI:0.925~1.296)均是ANVUGIB伴痛风急性发作的独立影响因素(P<0.05)。结论有无输血、是否联用碳酸氢钠、奥美拉唑、艾司奥美拉唑、尿酸水平均是ANVUGIB伴痛风急性发作的影响因素。对这些因素加以了解,可以更好地预防ANVUGIB患者中的痛风发作。
Objective To explore the influencing factors of gout attacks in patients of acute non-variceal upper gastrointestinal bleeding(ANVUGIB).Methods A total of 105 patients with ANVUGIB admitted to Suizhou Central Hospital from June 2018 to June 2022 were selected as the research objects.The patients were divided into gout attack group(29 cases)and gout non attack group(76 cases).Single factor regression and multi factor regression were applied to analyze the influencing factors of gout attacks.Results Single factor analysis result prompted that there were statistically significant differences in the comparison of levels of body mass index(BMI),blood biochemical indicator total cholesterol(TC)and triglycerides(TG)(P<0.05).The results of multiple logistic regression analysis showed that,whether blood transfusion or not(β=0.218,OR=1.127,95%CI:1.013-1.296),whether combined use of Sodium Bicarbonate or not(β=0.374,OR=1.232,95%CI:0.913-1.384)、Omeprazole(β=0.283,OR=1.093,95%CI:0.728-1.138),Esomeprazole(β-0.103,OR=0.957,95%CI:0.649-1.264),uric acid level(β=0.329,OR=1.192,95%CI:0.925-1.296)were the independent influencing factors for acute gout attacks in ANVUGIB(P<0.05).Conclusion Whether blood transfusion or not,whether combined use of Sodium Bicarbonate or not,Omeprazole,Esomeprazole and uric acid level were the influencing factors for acute gout attacks in ANVUGIB.Understanding these factors,can better prevent gout attacks in patients with ANVUGIB.
作者
郭建超
陈志勇
周琳
GUO Jianchao;CHEN Zhiyong;ZHOU Lin(Department of Gastroenterology,Suizhou Central Hospital,Affiliated Suizhou Hospital of Hubei Medical College,Hubei Province,Suizhou441300,China)
出处
《中国当代医药》
2025年第5期52-56,共5页
China Modern Medicine
基金
湖北省随州市卫生健康委科研项目(2021SZ32022)。
